Abstract. Oral cancer is one of the leading types of cancer and remains the most common cause of cancer-related mortality in Asia. The pathogenesis of oral cancer is complicated and, due to lack of accurate diagnostic methods and efficient treatment strategies, oral cancer is responsible for a large number of deaths. Therefore, there is an urgent need for developing novel diagnostic tools and targeted therapies. MicroRNAs (miRNAs) represent a class of small non-coding RNAs that are key elements and play critical regulatory roles in the pathological processes of various diseases. miRNAs are widely distributed in body fluids and are specifically expressed in different cancers, and they may represent effective biomarkers that may be used for early detection of oral cancer. In addition, miRNAs are involved in oral cancer development, progression and prognosis by targeting a broad range of mRNAs that may be of therapeutic value for oral cancer. The aim of the present review was to summarize the role of miRNAs as new diagnostic tools and potential therapeutic targets in oral cancer, and investigate the underlying molecular mechanisms.

Contents
1. Introduction
2. Expression profile of miRNAs in oral cancer
3. Therapeutic effects of miRNAs in oral cancer
4. Discussion and outlook

1. Introduction

Oral cancer is a type of head and neck cancer and its main subtype is oral squamous cell carcinoma (OSCC) (1). OSCC occurs in the oral cavity, which includes the tongue, floor of the mouth, buccal mucosa and alveolar rim (2). OSCC presents a major global health concern, with an estimated >300,000 cases per annum (3) and ∼1.8 million deaths (4). Currently, the diagnosis and treatment of OSCC represent a clinical challenge.

miRNAs are a class of small non-coding RNAs that are involved in the regulation of a variety of physiological processes by targeting specific mRNAs (5). miRNAs have been reported to play an important regulatory role in cancer occurrence and progression (6), and they may be of value as targets in oral cancer treatment (7). Due to their stability in human peripheral blood and body fluids and disease-specific expression, an increasing number of studies indicate that miRNAs may represent an ideal set of biomarkers applied in early diagnosis and prognosis of cancers (8).

The focus of the present review was the detailed regulatory role of miRNAs in oral cancer and their value in diagnosis and treatment. The conclusions of this review may contribute to the early diagnosis and targeted therapy of oral cancer.

2. Expression profile of miRNAs in oral cancer

miRNAs are a family of short, single-stranded, small non-coding RNAs, containing ~20-22 nucleotides (9). The miRNA expression profiles and levels differ between patients with cancer and healthy individuals, and they are implicated...
in human carcinogenesis (10,11). According to their chemical and structural properties, circulating miRNAs are stable in the serum, plasma and other body fluids (8), and they may be considered as potential clinical diagnostic and prognostic biomarkers.

**miRNAs may be novel diagnostic biomarkers in oral cancer.** The occurrence of oral cancer is multifactorial, and is accompanied by genetic and epigenetic instability (12). With the widespread application of next-generation sequencing, a growing number of studies have demonstrated that certain miRNAs are differentially expressed in oral cancer. In addition, the results of receiver operating characteristic (ROC) curve and area under the curve (AUC) analysis have indicated that the differentially expressed miRNAs may help distinguish patients with oral cancer from healthy subjects (13,14). As revealed in Table I (13-31), 35 miRNAs were screened, which were reported in the last 5 years with a ROC (AUC) >0.500. For example, Momen-Heravi et al reported that upregulated miR-27b and downregulated miR-136 derived from the saliva were able to differentiate between patients with oral cancer and healthy subjects (15). The ROC (AUC) of miR-21 extracted from oral cytology and miR-99a from the serum were up to 0.910 (16) and 0.911 (17), respectively. Gombos et al reported that miR-155 derived from tissues was able to distinguish between patients with oral cancer and healthy individuals [ROC (AUC)=0.925] (13). These data revealed that miRNAs originating from different samples may be considered as biomarkers for oral cancer diagnosis.

**miRNAs as novel prognostic biomarkers in oral cancer.** The expression profiles of certain miRNAs have demonstrated a positive correlation with clinical stage, metastasis and patient survival, indicating that these miRNAs may be considered as prognostic indices in oral cancer. Lai et al revealed that dysregulated miR-31-5p expression enhanced OSCC cell migration and invasion and accelerated oral cancer progression (32). In recent years, miRNAs have been reported to be strongly correlated with the survival of oral cancer patients. Chen et al indicated that patients with high expression level of miR-99a displayed a better prognosis and longer overall survival (17). Supic et al revealed that patients with miR-183 overexpression had markedly shorter overall survival and higher risk of poor outcome (23). Zheng et al reported that miR-503-5p, miR-450b-5p, miR-27a-3p, miR-181a-5p and miR-183-5p were overexpressed in patients with oral cancer, and they were all highly associated with cancer cell proliferation, advanced clinical stage and poor prognosis (33). Cheng et al revealed that the expression level of miR-455-5p was associated with the nodal status, stage and overall survival of the patients, suggesting that miR-455-5p may be a promising prognostic marker for predicting the outcome of patients with oral cancer (34). We herein also summarized other miRNAs that may be of prognostic value in oral cancer (Table II). All the aforementioned data indicated that miRNAs may be valuable prognostic indicators in oral cancer.

**3. Therapeutic effects of miRNAs in oral cancer**

miRNAs play a key role in regulating the translation or degradation of mRNAs by interacting with the 3’ untranslated region (3’UTR) or coding region of mRNAs and regulating the expression level of their target genes (35). miRNAs are involved in the cellular processes of cancer, such as inflammation, proliferation, stress response, growth, apoptosis, survival and migration (10). Therefore, manipulating miRNA expression in cancer has been attracting increasing attention as a novel therapeutic strategy. It was reported that miR-24-3p, miR-155-5p and miRNA-10a may significantly promote the proliferation of oral cancer cells (18,36,37). These findings suggested that silencing the expression of specific miRNAs may prevent the progression of oral cancer. Conversely, numerous miRNAs have been revealed to have an anticancer function. miR-6887-5p, miR-34a-5p and miR-142-3p markedly suppressed the proliferation of oral cancer cells (38-40). In addition, certain miRNAs, such as miR-204-5p and miR-34a-5p, exert their anticancer effects by inhibiting the aggressiveness and metastasis of oral cancer cells (39,41). The targets and functional roles of miRNAs are listed in Table II (17-19,32,33,36-54).

**miRNAs and oral cancer occurrence and progression.** Accumulating evidence indicates that miRNAs play a key role in the occurrence and progression of oral cancer. The protein kinase B (AKT) and mammalian target of rapamycin (mTOR) pathways are known to participate in the regulation of oral cancer occurrence (56). Manikandan et al revealed that >40 differentially expressed miRNAs in OSCC may activate the AKT pathway (57). miR-218 can inhibit the activation of mTOR/AKT pathway by targeting Rictor, and then suppress oral carcinogenesis (58). In oral cancer, miR-99 has been revealed to decreased the expression level of mTOR by directly binding with mTOR mRNA, thereby promoting cancer cell growth and increasing tumor size (59,60). The expression level of miR-455-5p has been revealed to be regulated by the TGF-β-dependent pathway, which subsequently promotes oral tumorigenesis by downregulating ubiquitin-conjugating enzyme E2B (UBE2B) (34). Chen et al revealed that CD36 contributed to the proliferation and invasion of OSCC, and miR-1254 may inhibit the progression of OSCC by partially downregulating the expression level of CD36 (61). In addition, inhibiting the expression of miR-423-5p may rescue the carcinogenic effect of IncRNA CASC9 by silencing the expression of SRY-box transcription factor 12 (SOX12) (62). These data revealed that miRNAs participate in oral carcinogenesis and progression by regulating their target genes.

**miRNAs and oral cancer cell proliferation and apoptosis.** The proliferation and apoptosis of oral cancer cells are regulated by multiple factors, with an increasing number of studies demonstrating that miRNAs are involved in the regulation of these cellular processes. Rastogi et al reported that in vitro restoration of miR-377 suppressed OSCC cell growth and induced apoptosis by regulating HDAC9 and its pro-apoptotic target, NLR4A1/Nur77 (63). miR-23a-3p may suppress proliferation
and promote apoptosis of OSCC cells by targeting fibroblast growth factor 2 (FGF1) (64). By contrast, it was reported that miR-155 contributed to oral cancer cell proliferation, inhibited cell apoptosis and reduced the sensitivity of oral cancer cells to DDP by downregulating Foxo3a expression (65). Furthermore, miR-155 promoted cell cycle progression and cell proliferation and suppressed apoptosis by inhibiting p27Kip1 expression (66).

**miRNAs and oral cancer cell migration, invasion and metastasis.**

The migration, invasion and metastasis of oral cancer cells are highly associated with the therapeutic strategy. miRNAs are involved in the regulation of these processes in oral cancer cells. Fang *et al* reported that miR-204-5p suppressed oral cancer cell aggressiveness, viability and migration by targeting and inhibiting: Huntingtin-interacting protein 1 (HIP1) expression (41). Overexpression of miR-143 and miR-145 in OSCC cells markedly suppressed the expression of activin A, and suppressed the migration and invasion of oral cancer cells, prevented lymph node metastasis, increased tumor differentiation and prolonged the survival of the patients (67). Huang *et al* revealed that enhancing the expression of miR-491-5p significantly downregulated the expression of GPCR kinase 2 interacting protein 1 (GIT1),

| No. | miRNAs     | Sample type     | Expression level in oral cancer vs. normal sample | ROC (AUC) (Refs.) |
|-----|------------|-----------------|--------------------------------------------------|------------------|
| 1   | miR-21     | Oral cytology   | Upregulated                                      | 0.910 (16)       |
| 2   | miR-24-3p  | Saliva          | Upregulated                                      | 0.738 (18)       |
| 3   | miR-31-5p  | Serum           | Upregulated                                      | 0.661 (19)       |
| 4   | miR-512-3p | Saliva          | Upregulated                                      | 0.847 (20)       |
| 5   | miR-412-3p | Saliva          | Upregulated                                      | 0.871 (20)       |
| 6   | miR-222-3p | Plasma          | Upregulated                                      | 0.702 (21)       |
| 7   | miR-150-5p | Plasma          | Upregulated                                      | 0.520 (21)       |
| 8   | miR-423-5p | Plasma          | Upregulated                                      | 0.677 (21)       |
| 9   | miR-548b   | Tissue          | Upregulated                                      | 0.651 (22)       |
| 10  | miR-18a    | Tissue          | Upregulated                                      | 0.682 (22)       |
| 11  | miR-183    | Tissue          | Upregulated                                      | 0.700 (23)       |
| 12  | miR-483-5p | Serum           | Upregulated                                      | 0.850 (24)       |
| 13  | miR-125b   | Plasma          | Upregulated                                      | 0.966 (25)       |
| 14  | miRNA-184  | Saliva          | Upregulated                                      | 0.860 (26)       |
| 15  | miR-196a   | Plasma          | Upregulated                                      | 0.864 (27)       |
| 16  | miR-196b   | Plasma          | Upregulated                                      | 0.960 (27)       |
| 17  | miR-494    | Whole blood     | Upregulated                                      | 0.720 (28)       |
| 18  | miR-3651   | Whole blood     | Upregulated                                      | 0.800 (28)       |
| 19  | miR-27b    | Saliva          | Upregulated                                      | 0.964 (15)       |
| 20  | miR-155    | Tissues         | Upregulated                                      | 0.925 (13)       |
| 21  | miR-221    | Tissues         | Upregulated                                      | 0.901 (13)       |
| 22  | miR-16     | Serum           | Upregulated                                      | 0.840 (14)       |
| 23  | let-7b     | Serum           | Upregulated                                      | 0.820 (14)       |
| 24  | miR-3651   | Tissue          | Downregulated                                    | 0.779 (29)       |
| 25  | miR-99a    | Serum           | Downregulated                                    | 0.911 (17)       |
| 26  | miR-542-3p | Plasma          | Downregulated                                    | 0.820 (30)       |
| 27  | miR-375    | Oral cytology   | Downregulated                                    | 0.910 (16)       |
| 28  | miR-139-5p | Saliva          | Downregulated                                    | 0.805 (31)       |
| 29  | miRNA-145  | Saliva          | Downregulated                                    | 0.680 (26)       |
| 30  | miR-186    | Whole blood     | Downregulated                                    | 0.690 (28)       |
| 31  | miR-136    | Saliva          | Downregulated                                    | 0.968 (15)       |
| 32  | miR-191    | Tissues         | Downregulated                                    | 0.887 (13)       |
| 33  | miR-333-3p | Serum           | Downregulated                                    | 0.820 (14)       |
| 34  | miR-29a    | Serum           | Downregulated                                    | 0.820 (14)       |
| 35  | miR-223    | Serum           | Downregulated                                    | 0.810 (14)       |

ROC, receiver operating characteristic; AUC, area under the curve.
thereby suppressing OSCC cell migration in vitro and lung metastasis in vivo (68). Conversely, overexpression of miR-21 was associated with perineural invasion and worse prognosis in OSCC patients (69). Tu et al. reported that overexpression of miR-372 and miR-373 were associated with nodal metastasis, lymph vascular invasion and poor survival by regulating the expression of large tumor suppressor kinase 2 (LATS2) in OSCC cells (70).

miRNAs as novel therapeutic tools in oral cancer. A large volume of evidence has demonstrated that miRNAs play key roles in oral cancer occurrence and growth, cancer cell migration and invasion, cancer progression and patient prognosis. This evidence suggests that miRNAs may be considered as novel therapeutic tools for oral cancer.

It was reported that upregulation of miR-375 markedly inhibited cell proliferation, induced cell cycle arrest in the G0/G1 phase, promoted apoptosis and increased radiosensitivity in OSCC cells, suggesting that miR-375 may be a potential therapeutic target for OSCC patients (71). miR-494-3p was able to enhance the radiosensitivity of OSCC cells by promoting cellular senescence (72). Min et al. revealed that overexpression of miR-148a in cancer-associated fibroblasts significantly decreased the migration and invasion abilities of oral cancer cells by directly targeting WNT10B, suggesting that miR-148a may be a novel promising target for the treatment of OSCC (73). Chen et al. reported that miR-1254 may inhibit the progression of OSCC, and restoring miR-1254 expression may represent an effective treatment strategy for

Table II. Targets and functional roles of miRNAs in oral cancer.

| No. | miRNAs | Targets | Pathoclinical appearances |
|-----|--------|---------|---------------------------|
|     |        |         | Metastatic potential | Growth potential | Invasive status | Prognosis of patients | (Refs.) |
| 1   | miR-24-3p | PER1 | ↑ | ↑ | / | / | (18) |
| 2   | miR-31-5p | ACOX1 | / | / | / | / | (19,32) |
| 3   | miR-99a | / | / | / | / | / | (17) |
| 4   | miR-183 | / | / | / | / | / | (23) |
| 5   | miR-204-5p | HIP1 | ↓ | ↓ | / | / | (41) |
| 6   | miR-6887-5p | HBp17 | / | ↓ | / | / | (38) |
| 7   | miR-155-5p | ARID2 | ↑ | ↑ | ↑ | / | (36) |
| 8   | hsa-mir-99b-3p | / | / | / | / | / | (42) |
| 9   | hsa-mir-100-5p | / | / | / | / | / | (42) |
| 10  | miRNA-10a | GLUT1 | / | ↑ | / | / | (37) |
| 11  | hsa-miR-let.7i-3p | / | / | / | / | / | (43) |
| 12  | miR-450a | TMEM182 | / | / | ↑ | / | (44) |
| 13  | miR-29b-1-5p | CDH1 | / | / | / | / | (45) |
| 14  | miR-210-3p | RGMA | / | ↑ | / | / | (46) |
| 15  | miR-545 | RIG-I | ↓ | ↓ | / | / | (47) |
| 16  | miR-21 | TNF-α | / | ↑ | / | / | (48) |
| 17  | miR-503-5p, miR-450b-5p, miR-27a-3p, miR-181a-5p and miR-183-5p | RORα | / | ↑ | / | / | (33) |
| 18  | miR-211 | BIN1 | ↑ | ↑ | ↑ | / | (49) |
| 19  | miR-34a-5p | AXL | ↓ | ↓ | / | / | (39) |
| 20  | miR-134 | PDCD7 | ↑ | / | / | / | (50) |
| 21  | miR-203 | Bmi-1 | / | / | / | / | (51) |
| 22  | miR-196a-5p | BIRC3 | / | ↓ | / | / | (52) |
| 23  | miR-30a-5p | FAP | ↓ | ↓ | / | / | (53) |
| 24  | miR-1246 | DENND2D | ↑ | / | ↑ | / | (54) |
| 25  | miR-142-3p | TGFB1 | ↓ | ↓ | / | / | (40) |

↑: Indicates a promoting effect; ↓: Indicates an inhibitory effect; /: Indicates an unknown effect. PER1, period 1 gene; ACOX1, acyl-CoA oxidase 1; HIP1, Huntingtin-interacting protein 1; HBp17, heparin-binding protein 17; ARID2, AT-rich interaction domain 2; GLUT1, glucose transporter 1; TMEM182, transmembrane protein 182; CDH1, E-cadherin gene 1; RGMA, repulsive guidance molecule A; RIG-I, retinoic acid-inducible gene-I; TNF-α, tumor necrosis factor α; RORα, retinoic acid receptor-related orphan receptor α; BIN1, bridging integrator 1; AXL, receptor tyrosine kinase; PDCD7, programmed cell death 7; Bmi-1, B-cell-specific Moloney murine leukemia virus integration site 1; BIRC3, baculoviral IAP repeat-containing 3; FAP, fibroblast activation protein; DENND2D, differentially expressed in normal cells and neoplasia domain containing 2D; TGFB1, TGF-β receptor 1.
Similarly, miR-377 and miR-23a-3p suppressed cell proliferation and promoted apoptosis in OSCC, suggesting that both miR-377 and miR-23a-3p may prove to be of value as therapeutic targets for OSCC in the future (63,64). In summary, all the aforementioned data suggest that miRNAs may be considered as effective anticancer targets, and they may be used to develop novel treatment strategies for oral cancer.

4. Discussion and outlook

Although great progress has been made in the diagnosis of oral cancer, the methods for early diagnosis and prognosis require further improvements. Early diagnosis may markedly increase the effectiveness of treatment and prolong the survival of patients with oral cancer. Therefore, it is urgent to develop novel biomarkers with higher accuracy, sensitivity and specificity, that are more convenient for clinical detection.

With the development of sequencing technology, an increasing number of miRNAs have been revealed to be specifically expressed in a variety of samples from oral cancer (15,16). These miRNAs also play a key role in regulating cellular processes and behaviors (66,68). miRNAs may represent optimal biomarkers and new therapeutic tools for oral cancer. However, although the miRNAs aforementioned appear to be promising candidates as biomarkers, they require further investigation, including biological study and clinical verification. Furthermore, the source, formation and regulatory networks of miRNAs are quite complex, and the expression level of miRNAs in different stages of oral cancer is also different. Hence, it is necessary to elucidate the mechanism of miRNA formation, which may contribute to early diagnosis, targeted therapy and prognosis evaluation of oral cancer patients. Notably, the therapeutic miRNAs that may be used to develop novel targeted drugs require further research in terms of suitable and effective in vivo delivery methods. Identifying key targets and building a targeted delivery system (such as a nano-miRNA system) will be our future research priorities.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Science Foundation of China (grant no. 81372908).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

JW, RY, JY designed the review and edited the manuscript. JW, NL, XL wrote the manuscript. JW, RY and ZC collected and analyzed data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
43. Falzone L, Lupo G, La Rosa GR, Crimi S, Anfuso CD, Salemi R, Rapisarda E, Libra M and Candido S: Identification of Novel MicroRNAs and their diagnostic and prognostic significance in oral squamous cell carcinoma. Cancers 6: 160-190, 2019.

44. Jiang EW, Shiha SG, Peng HY, Chen YW, Chuu CP, Hsiao JR, Lu YC and Chang YJ: TNF-α-induced miR-450a mediates TMEM182 expression to promote oral squamous cell carcinoma motility. PLoS One 14: e0213463, 2019.

45. Kuribara-Shimomura M, Sashihara T, Shimomura H, Nakashima C and Kirita T: MiR-298-1-5p is the oncogenic activity of induces the epithelial-mesenchymal transition in oral squamous cell carcinoma. J Clin Med 24: 273, 2019.

46. Lu Y, Li Y, Wang Z, Xie S, Wang Q, Lei X, Ruan Y and Li J: Downregulation of RGMa by HIF-1α/miR-210-3p axis promotes cell proliferation in oral squamous cell carcinoma. Biomed Pharmacother 112: 108608, 2019.

47. Yuan G, Wu H, Du Y and He F: Tumor suppressor role of microRNA-545 in oral squamous cell carcinoma. Oncol Lett 17: 2063-2069, 2019.

48. Qiu YF, Wang MX, Meng LN, Zhang R and Wang W: MiR-21 regulates proliferation and apoptosis of oral cancer cells through TNF-α. Eur Rev Med Pharmacol Sci 22: 7735-7741, 2018.

49. Zheng J, Wang J, Jia Y, Liu T, Duan Y, Liang X and Liu L: microRNA-211 promotes proliferation, migration, and invasion ability of oral squamous cell carcinoma cells via targeting the bridging integrator 1 protein. J Cell Biochem 120: 4644-4653, 2019.

50. Peng SY, Tu HF, Yang CC, Wu CH, Liu CJ, KWang and Lin SC: miR-134 targets PDCD7 to reduce E-cadherin expression and enhance oral cancer progression. Int J Cancer 143: 2892-2904, 2018.

51. Kim JS, Choi DW, Kim CS, Yu SK, Kim HH, Go DS, Lee SA, Moon SM, Kim SG, Chun HS, et al: MicroRNA-203 induces apoptosis by targeting in YD-38 oral cancer cells. Anticancer Res 38: 1695-1702, 2018.

52. Wang L, Wei Y, Yan Y, Wang H, Yang J, Zheng Z, Zha J, Bo P, Tang Y, Guo X, et al: CircDOCK1 suppresses cell apoptosis via inhibition of miR-196a-5p by targeting BIRC3 in OSCC. Oncol Rep 39: 951-966, 2018.

53. Ruan P, Tao Z and Tan A: Low expression of miR-30a-5p induced the proliferation and invasion of oral cancer via promoting the expression of FAP. Biosci Rep 38: BSR20171027, 2018.

54. Sakha S, Muramatsu T, Ueda K and Inazawa J: Exosomal microRNA miR-1246 induces cell motility and invasion through the regulation of DENND2D in oral squamous cell carcinoma. Cell Res 28: 3477-3485, 2018.

55. Wang L, Wei Y, Yan Y, Wang H, Yang J, Zheng Z, Zha J, Bo P, Tang Y, Guo X, et al: CircDOCK1 suppresses cell apoptosis via inhibition of miR-196a-5p by targeting BIRC3 in OSCC. Oncol Rep 39: 951-966, 2018.

56. Ruan P, Tao Z and Tan A: Low expression of miR-30a-5p induced the proliferation and invasion of oral cancer via promoting the expression of FAP. BioRep 38: BSR20171027, 2018.

57. Sakha S, Muramatsu T, Ueda K and Inazawa J: Exosomal microRNA miR-1246 induces cell motility and invasion through the regulation of DENND2D in oral squamous cell carcinoma. Cell Res 28: 3477-3485, 2018.

58. Su F, Chen HH, Cheng P, Zhang CB and Wu Y: MicroRNA-155 regulates oral squamous cell carcinoma cell migration and invasion by targeting FGFR2. Pathol Res Pract 215: 660-667, 2019.

59. Li X, Liu K, Zhou W and Jiang Z: MiR-155 targeting FoxO3a regulates oral cancer cell proliferation, apoptosis, and DDR resistance through targeting FoxO3a. Cancer Biomark 27: 105-111, 2020.

60. Su F, Chen HH, Cheng P, Zhang CB and Wu Y: MicroRNA-155 regulates oral squamous cell carcinoma cell migration and invasion by targeting FGFR2. Pathol Res Pract 215: 660-667, 2019.

61. Li X, Liu K, Zhou W and Jiang Z: MiR-155 targeting FoxO3a regulates oral cancer cell proliferation, apoptosis, and DDR resistance through targeting FoxO3a. Cancer Biomark 27: 105-111, 2020.

62. Chen X, Xu H, Du Y and He F: Tumor suppressor role of microRNA-545 in oral squamous cell carcinoma. Oncol Lett 17: 2063-2069, 2019.

63. Qiu YF, Wang MX, Meng LN, Zhang R and Wang W: MiR-21 regulates proliferation and apoptosis of oral cancer cells through TNF-α. Eur Rev Med Pharmacol Sci 22: 7735-7741, 2018.

64. Zheng J, Wang J, Jia Y, Liu T, Duan Y, Liang X and Liu L: microRNA-211 promotes proliferation, migration, and invasion ability of oral squamous cell carcinoma cells via targeting the bridging integrator 1 protein. J Cell Biochem 120: 4644-4653, 2019.

65. Peng SY, Tu HF, Yang CC, Wu CH, Liu CJ, KWang and Lin SC: miR-134 targets PDCD7 to reduce E-cadherin expression and enhance oral cancer progression. Int J Cancer 143: 2892-2904, 2018.

66. Kim JS, Choi DW, Kim CS, Yu SK, Kim HH, Go DS, Lee SA, Moon SM, Kim SG, Chun HS, et al: MicroRNA-203 induces apoptosis by targeting in YD-38 oral cancer cells. Anticancer Res 38: 3477-3485, 2018.

67. Wang L, Wei Y, Yan Y, Wang H, Yang J, Zheng Z, Zha J, Bo P, Tang Y, Guo X, et al: CircDOCK1 suppresses cell apoptosis via inhibition of miR-196a-5p by targeting BIRC3 in OSCC. Oncol Rep 39: 951-966, 2018.

68. Ruan P, Tao Z and Tan A: Low expression of miR-30a-5p induced the proliferation and invasion of oral cancer via promoting the expression of FAP. BioRep 38: BSR20171027, 2018.

69. Sakha S, Muramatsu T, Ueda K and Inazawa J: Exosomal microRNA miR-1246 induces cell motility and invasion through the regulation of DENND2D in oral squamous cell carcinoma. Cell Res 28: 3477-3485, 2018.

70. Su F, Chen HH, Cheng P, Zhang CB and Wu Y: MicroRNA-155 regulates oral squamous cell carcinoma cell migration and invasion by targeting FGFR2. Pathol Res Pract 215: 660-667, 2019.